Intervention Protocol

Naloxone for hepatic encephalopathy

  1. Shao Liang Sun2,
  2. Ke Hu Yang3,
  3. Tao Jing1,*,
  4. Jing Zhang4,
  5. Jin Hui Tian3,
  6. Bin Ma3,
  7. Hong Yin5

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 7 OCT 2009

Assessed as up-to-date: 4 AUG 2009

DOI: 10.1002/14651858.CD008177


How to Cite

Sun SL, Yang KH, Jing T, Zhang J, Tian JH, Ma B, Yin H. Naloxone for hepatic encephalopathy (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD008177. DOI: 10.1002/14651858.CD008177.

Author Information

  1. 1

    The Evidence-Based Medicine Centre, Lanzhou University, School of Basic Medical Sciences of Lanzhou University, Lanzhou City, China

  2. 2

    Lanzhou University, The Centre of Evidence Based Medicine, Lanzhou City, Gansu Province, China

  3. 3

    Lanzhou University, Centre of Evidence Based Medicine, Lanzhou City, Gansu, China

  4. 4

    Gastroenterology Department of Liaocheng People's Hospital, Liaocheng City, Shandong province, China

  5. 5

    Lanzhou University, First Affiliated Hospital of Lanzhou University, Lanzhou City, Gansu, China

*Tao Jing, School of Basic Medical Sciences of Lanzhou University, The Evidence-Based Medicine Centre, Lanzhou University, Lanzhou City, China. jingtaoebm@163.com.

Publication History

  1. Publication Status: New
  2. Published Online: 7 OCT 2009

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the beneficial and harmful effects of naloxone for patients with hepatic encephalopathy.